Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. (INBS) is a progressive life sciences company committed to enhancing health care through innovative non-invasive diagnostic tests. The company's primary focus lies in developing real-time monitoring solutions that aid patients and health practitioners in managing chronic diseases efficiently. Through its cutting-edge Biosensor Platform, Intelligent Bio Solutions Inc. is pioneering diagnostic tests that are urgently required to improve patient outcomes and streamline medical diagnostics.
One of the company's significant advancements is in the realm of portable drug abuse testing. Utilizing fingerprint sweat analysis, INBS offers a non-invasive, hygienic, and rapid drug screening solution. This technology is engineered to detect the recent use of substances such as opioids, cocaine, methamphetamines, benzodiazepines, and marijuana, making it an invaluable tool in both clinical and legal settings.
Intelligent Bio Solutions Inc. has demonstrated substantial growth and success, as evidenced by an impressive year-over-year unaudited revenue increase of 80% for the fiscal third quarter and 193% for the nine months ending March 31, 2024. The company also reported its highest quarterly cartridge sales since acquiring Intelligent Fingerprinting in 2022, highlighting the growing demand and effectiveness of its products.
For more information, visit: http://www.ibs.inc/.
Rhea-AI Summary
Intelligent Bio Solutions Inc. (INBS) has entered into an agreement with warrant holders to exercise certain existing Series E Warrants, resulting in the purchase of 606,064 shares of common stock. The gross proceeds to the company are expected to be approximately $1.77 million. The exercising holders will receive new unregistered warrants to purchase shares of common stock in a private placement. The company intends to use the net proceeds for working capital and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the warrant exercise transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.82%
Tags
-
Rhea-AI Summary
Intelligent Bio Solutions Inc. (INBS) reports a 114% increase in revenue for the fiscal second quarter and a 337% increase for the six months ended December 31, 2023. The company expects unaudited revenue of $1.56 million for the six months, a significant rise from the previous year. INBS also anticipates a 30% rise in cartridge sales and a 91% rise in reader sales. The company's expansion into new markets and global footprint has contributed to the revenue growth, with plans for further expansion in the Asia-Pacific region. The positive revenue growth numbers reflect the increasing demand for the company's drug screening solution and its aim to maintain this upward trajectory throughout 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
146.89%
Tags
-
Rhea-AI Summary
Intelligent Bio Solutions Inc. (INBS) reports that customers in construction, manufacturing, and logistics are experiencing operational benefits, including cost reductions and improved productivity, after deploying the Intelligent Fingerprinting Drug Screening System. The system offers a non-invasive, quick, and easy solution for workplace drug testing, leading to significant savings for companies like P&O Ferries, Auctus Management Group, DGP Plc, and Robinson Brothers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.18%
Tags
Rhea-AI Summary
Intelligent Bio Solutions Inc. (INBS) announces that leading UK timber processor and packaging manufacturer, James Jones & Sons Ltd, is implementing the revolutionary portable Intelligent Fingerprinting Drug Screening System for in-house drug testing. The system will be used across all 25 UK locations, covering 1,300 employees and enabling a random testing program to support the company's new substance misuse policy. The system offers non-invasive, rapid, and cost-effective testing, providing results in just ten minutes. The company has purchased 11 systems for deployment and is considering expanding its use to its Australian operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.1%
Tags
-
Rhea-AI Summary
Intelligent Bio Solutions Inc. (INBS) has announced a 1-for-12 reverse split of its common stock, effective on January 26, 2024. The split is aimed at increasing the per-share trading price and ensuring compliance with Nasdaq’s listing requirements. The reverse split will result in every 12 shares being combined into one share, with adjustments to outstanding equity-based awards and other equity rights. The split will not affect the par value of the common stock or the number of authorized shares, leaving the company with approximately 1,494,223 shares of common stock issued and outstanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25%
Tags
-
Rhea-AI Summary
Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced that DGP Plc has selected the Intelligent Fingerprinting Drug Screening System to enable in-house drug testing for its 450 employees and contractors, simplifying and speeding up the process. The portable system allows for faster, more convenient, and flexible workplace drug testing, resulting in overall cost savings and improved productivity due to minimal disruption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.05%
Tags
Rhea-AI Summary
Intelligent Bio Solutions Inc. (INBS) announced that Robinson Brothers, a UK chemical manufacturer, is now using its portable Intelligent Fingerprinting Drug Screening System for in-house drug testing. The system offers portability, flexibility, and ease-of-use, enabling random testing and for cause tests across the business. This move aims to improve efficiency and productivity for Robinson Brothers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
-
Rhea-AI Summary
Intelligent Bio Solutions Inc. (INBS) has received NATA accreditation for its Intelligent Fingerprinting Drug Screening Solution, aligning with international standards and providing broad opportunities for the company. The accreditation supports the business operations and market presence, positioning INBS as a trusted partner for organizations with stringent drug and alcohol testing policies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.22%
Tags
-
Rhea-AI Summary
Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced that leading pan-European ferry and logistics company, P&O Ferries, is now using the revolutionary portable Intelligent Fingerprinting Drug Screening System to support its drug and alcohol testing policy. The system is expected to reduce P&O Ferries’ overall drug testing costs by 90%. P&O Ferries will deploy the system at its three UK ferry port sites at Larne in Northern Ireland, as well as Hull and Dover in England.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
Rhea-AI Summary
Intelligent Bio Solutions Inc. (NASDAQ: INBS) announced that Titan Cranes and Rigging Pty Ltd. has adopted the Company's Intelligent Fingerprinting Drug Screening System. Titan is Australasia’s leading specialist material handling company, contributing to Australia’s construction industry, which generates over $360 billion in annual revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.06%
Tags
FAQ
What is the current stock price of Intelligent Bio Solutions (INBS)?
The current stock price of Intelligent Bio Solutions (INBS) is $1.73 as of February 4, 2025.
What is the market cap of Intelligent Bio Solutions (INBS)?
The market cap of Intelligent Bio Solutions (INBS) is approximately 8.1M.
What does Intelligent Bio Solutions Inc. specialize in?
Intelligent Bio Solutions Inc. specializes in developing non-invasive, real-time monitoring and diagnostic tests for managing chronic diseases and portable drug abuse testing.
What is the Biosensor Platform?
The Biosensor Platform is a technology developed by INBS for creating real-time diagnostic tests to assist in managing chronic illnesses and other medical conditions.
How does INBS's drug abuse testing technology work?
INBS uses fingerprint sweat analysis to offer a non-invasive, hygienic, and quick method of screening for recent drug use, including opioids, cocaine, and more.
What recent financial achievements has Intelligent Bio Solutions Inc. reported?
The company reported an 80% increase in year-over-year unaudited revenue for the fiscal third quarter and a 193% increase for the nine months ending March 31, 2024.
When did INBS achieve its highest quarterly cartridge sales?
INBS reported its highest quarterly cartridge sales since 2022, following the acquisition of Intelligent Fingerprinting.
Who are the primary contacts for Intelligent Bio Solutions Inc.?
Company-related inquiries can be directed to info@ibs.inc. For media-related queries, contact Cheryl Billson at cheryl.billson@commacomms.com or Valter Pinto at INBS@kcsa.com.
Where can I find more information about the company?
For more information about Intelligent Bio Solutions Inc., visit their official website at http://www.ibs.inc/.
What chronic diseases does INBS focus on with its diagnostic tests?
INBS focuses on creating diagnostic tests that assist in the management of various chronic diseases, though specific conditions are not detailed.
What substances can INBS's drug screening test detect?
INBS's drug screening test can detect recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.
How does the fingerprint sweat analysis benefit users?
The fingerprint sweat analysis is non-invasive, hygienic, and fast, providing a convenient and reliable method for drug abuse testing.
Intelligent Bio Solutions Inc.
Nasdaq:INBS
INBS Rankings
INBS Stock Data
8.15M
4.68M
3.02%
14.38%
8.69%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States of America
NEW YORK